Keurig Dr Pepper Inc (KDP)
Official siteCONSUMER DEFENSIVE • BEVERAGES - NON-ALCOHOLIC • NASDAQ
Market Cap: $49.46B
Last updated: Nov 17, 2026 at 11:06 AM ET
Keurig Dr Pepper Inc (KDP) Stock Forecast
Analysts expect Keurig Dr Pepper (KDP) to earn $2.30 per share in the fiscal year ending Dec 31, 2026, on revenue of $26.26B. Of 18 analysts, 13 rate the stock Buy or Strong Buy, 5 Hold and 0 Sell or Strong Sell, for a consensus of Buy. Over the last 30 days, 2 estimates for the fiscal year ending Dec 31, 2026 were revised up and 3 down.
Analyst Ratings
Scoring Strong Buy as 1 and Strong Sell as 5, the 18 ratings average 2.00, inside the Buy band from 1.5 up to 2.5. Buy and Strong Buy make up 72% of the ratings.
| Rating | Analysts | Share |
|---|---|---|
| Strong Buy | 5 | 27.8% |
| Buy | 8 | 44.4% |
| Hold | 5 | 27.8% |
| Sell | 0 | 0.0% |
| Strong Sell | 0 | 0.0% |
- Consensus
- Buy
- Total analysts
- 18
Price Target
Analyst price targets are part of paid GNG plans. See plans
Annual Estimates
From the first fiscal year below to the second, the EPS consensus rises 10.4% and revenue estimates rise 13.8%.
- Fiscal year ending Dec 31, 2026
- $2.30
- EPS consensus, revenue $26.26B
- Fiscal year ending Dec 31, 2027
- $2.54
- EPS consensus, revenue $29.89B
- Next report
- Feb 22, 2027
- Estimated
EPS range
Revenue range
| Fiscal year ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | $2.30 | $2.27 to $2.33 | 20 | $26.26B | $26.19B to $26.35B | 18 |
| Dec 31, 2027 | $2.54 | $2.42 to $2.60 | 20 | $29.89B | $28.94B to $30.39B | 18 |
Quarterly Estimates
The EPS consensus falls from $0.67 for the quarter ending Dec 31, 2026 to $0.49 for the quarter ending Mar 31, 2027.
EPS range
Revenue range
| Quarter ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | $0.67 | $0.62 to $0.75 | 18 | $7.71B | $7.41B to $8.11B | 16 |
| Mar 31, 2027 | $0.49 | $0.45 to $0.54 | 12 | $6.96B | $6.67B to $7.66B | 8 |
Estimate Revisions
Across the 2 periods below, the last 30 days brought 3 upward and 8 downward EPS revisions. Cuts outnumber raises in every period.
| Period | Up 30 days | Down 30 days |
|---|---|---|
| Fiscal year ending Dec 31, 2026 | 2 | 3 |
| Quarter ending Mar 31, 2027 | 1 | 5 |
EPS Trend
Over the last 90 days, the EPS consensus for the fiscal year ending Dec 31, 2026 has risen 0.4% from $2.29.
| Period | Now | 7 days ago | 30 days ago | 60 days ago | 90 days ago | Change |
|---|---|---|---|---|---|---|
| Fiscal year ending Dec 31, 2026 | $2.30 | $2.30 | $2.29 | $2.29 | $2.29 | +0.2% |
| Fiscal year ending Dec 31, 2027 | $2.54 | $2.54 | $2.53 | $2.53 | $2.53 | +0.1% |
| Quarter ending Mar 31, 2027 | $0.49 | $0.48 | $0.49 | $0.49 | $0.49 | -0.6% |
Frequently Asked Questions About KDP
What is the KDP stock forecast?
Consensus analyst estimates put Keurig Dr Pepper's EPS at $2.30 for the fiscal year ending Dec 31, 2026, on revenue of $26.26B. The consensus rating from 18 analysts is Buy.
How do analysts rate KDP stock?
Of 18 analysts covering Keurig Dr Pepper, 5 rate it Strong Buy, 8 Buy, 5 Hold, 0 Sell and 0 Strong Sell, for a consensus of Buy.
What EPS do analysts expect from KDP next year?
For the fiscal year ending Dec 31, 2026, the consensus EPS estimate is $2.30, with estimates from $2.27 to $2.33 from 20 analysts. For the fiscal year ending Dec 31, 2027, the consensus EPS estimate is $2.54, with estimates from $2.42 to $2.60 from 20 analysts.
What revenue do analysts expect from Keurig Dr Pepper next year?
For the fiscal year ending Dec 31, 2026, the consensus revenue estimate is $26.26B, with estimates from $26.19B to $26.35B. For the fiscal year ending Dec 31, 2027, the consensus revenue estimate is $29.89B, with estimates from $28.94B to $30.39B.
How many analysts cover KDP?
18 analysts rate Keurig Dr Pepper stock, and 20 analysts estimate its EPS for the fiscal year ending Dec 31, 2026.
KDP pages: Overview, Dividends, Earnings, Forecast, Financials, Valuation, Competitors